• USA sales orders up over 200% year-on-year
• Somfit home sleep testing sales building momentum
• FY25 guidance: sales >$55m, EBITDA >$5m

Compumedics Limited (ASX: CMP), a global medical device company, has announced that it will book record sales orders of more than $31m for H1 FY25, with the final number to be confirmed in early January. The company's USA sales orders continue to grow, up more than 200% compared to the same time last year, driven primarily by the sleep, Somfit home sleep testing, and brain research businesses. The Somfit quoted business in the USA has reached $6.3m (USD4.2m), with a recent initial sale to a large global CPAP player and success in new trials at large Independent Diagnostic Testing Facilities (IDTF's) in the USA. The addressable home sleep apnea test (HST) market in the USA is estimated to be between 3m and 4m HST's a year, representing a market opportunity between $150m (USD100m) and $300m (USD200m) for Compumedics. The company has also taken an initial $200k (EUR120k) Somfit sale in Europe, representing the initial market activity in the next large market opportunity for Somfit. Compumedics' FY25 guidance includes sales of more than $55m (excluding MEG) and EBITDA above $5m, with EBITDA weighted towards the second half due to marketing and development costs being expensed in the first half and sales benefits coming in the second half.

FY25 guidance: sales more than $55m (excluding MEG) and EBITDA above $5m.

Compumedics is well-placed to accelerate growth in the USA over the remainder of FY25, with new sales resources coming on board and the company progressing trials and demonstrations with 3 large IDTF's in the USA.